NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
Clinical Trials
34 trialsNCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT04592198 2025-03-24
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Xiamen LP Pharmaceutical Co., Ltd
Phase 2 Completed
NCT01836705 2025-03-05
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT03040726 2023-10-17
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT03674294 2023-02-08
CINV
Sun Yat-sen University
Phase 3 Completed
NCT01363479 2021-09-22
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT03097588 2021-07-12
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00553059 2020-10-09
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT02135510 2020-03-31
MEDEA
Amsterdam UMC, location VUmc
Phase 3 Completed
NCT00900757 2019-08-28
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Duke University
Phase 2 Completed
NCT03862144 2019-03-05
GIM15-NEPA
Consorzio Oncotech
Phase 2 Completed
NCT02557035 2018-06-20
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT02532634 2018-05-11
RAPA
Kangdong Sacred Heart Hospital
Phase 4 Completed
NCT00343863 2017-07-11
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
University of Washington
Phase NA Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00684463 2017-05-16
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT00306735 2016-12-05
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Eisai Inc.
Phase 2 Completed
NCT02203253 2016-08-24
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
China Medical University, China
Phase 3 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT01074697 2015-04-24
GAND-emesis
Odense University Hospital
Phase 3 Completed
NCT01046240 2015-01-27
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Completed
NCT01339260 2014-11-26
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT01640340 2013-11-07
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT00410488 2013-03-22
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
M.D. Anderson Cancer Center
Phase NA Completed
NCT01481831 2012-12-31
ESPNV
Shanghai Changzheng Hospital
Phase 4 Completed
NCT00412425 2012-05-04
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00415103 2009-09-18
AMENO-2
PETHEMA Foundation
Phase 4 Completed
NCT00666783 2008-04-25
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
Xijing Hospital
Phase 2 Completed